Date: 2016-04-20
Type of information: Presentation of results at a congress
phase: preclinical
Announcement: presentation of results at the American Association for Cancer Research (AACR) Annual Meeting
Company: Curis (USA - MA) Aurigene (India)
Product: AUPM-327
Action mechanism:
Disease:
Therapeutic area: Cancer - Oncology
Country:
Trial details:
Latest
news: * On April 20, 2016, Curis and its collaborator, Aurigene, presented data from a mucin-domain containing-3 (TIM-3) antagonist program. Data from this independent program within the collaboration with compounds that target PD-L1 and TIM-3 immune checkpoints were also presented. In vitro studies showed that AUPM-327, a representative molecule from the PD-L1/TIM-3 program, can rescue T cell functions that are inhibited by addition of PD-L1 or TIM-3 checkpoint proteins, but does not affect other checkpoint regulators such as VISTA, CTLA4, and LAG-3, demonstrating its selectivity. Additionally, daily oral administration of the PD-L1/TIM-3 antagonist resulted in anti-tumor activity in multiple syngeneic tumor models including melanoma and colon cancer.